SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rubens RD, Fogelman I. Bone metastases: diagnosis and treatment. New York: Springer-Verlag, 1991.
  • 2
    Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 48893.
  • 3
    Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 2919.
  • 4
    Kyle RA. Multiple myeloma: a review of 869 cases. Mayo Clin Proc 1975; 50: 2940.
  • 5
    Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991; 12(Suppl 1): S16.
  • 6
    Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987; 138: 14648.
  • 7
    Kanis JA, McCloskey EV, Taube T, O'Rourke N. Rationale for the use of bisphosphonates in bone metastases. Bone 1991; 12(Suppl 1): S1318.
  • 8
    Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998; 16: 38909.
  • 9
    Fleisch H. Bisphosphonates: mechanisms of action and clinical use in osteoporosis—an update. Horm Metab Res 1997; 29: 14550.
  • 10
    Fleisch H. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997; 29: 5562.
  • 11
    Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983; 74: 42132.
  • 12
    Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989; 2: 11802.
  • 13
    Cantwell BM, Harris AL. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcemia caused by cancer. BMJ 1987; 294: 4679.
  • 14
    Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988; 6: 7628.
  • 15
    Gucalp R, Ritch P, Wiernik PH, Sarma PRKA, Richman SP, Tauer K, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10: 13442.
  • 16
    Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate. J Bone Miner Res 1986; 1: 55562.
  • 17
    Sawyer N, Newstead C, Drummond A, Cunningham J. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate [APD]) as single shot treatment of hypercalcemia. Bone Miner 1990; 9: 1218.
  • 18
    Body JJ, Borkowski A, Cleeren A, Bijvoet OL. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 1986; 4: 117783.
  • 19
    Body JJ, Magritte A, Seraj F, Sculier JP, Borkowski A. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. J Bone Miner Res 1989; 4: 9238.
  • 20
    Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297304.
  • 21
    Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593602.
  • 22
    Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; 1: 1469.
  • 23
    Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 1988; 58: 6215.
  • 24
    Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988; 297: 7723.
  • 25
    Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 5965.
  • 26
    van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 4918.
  • 27
    Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983; 35: 8799.
  • 28
    Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992; 26: 12629.
  • 29
    Urwin GH, Percival RC, Harris S, Beneton MNC, Williams JL, Kanis SA. Generalized increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 7213.
  • 30
    Nemoto R, Nakamura I, Nishijima Y, Shiobara K, Shimizu M, Takehara T, et al. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption. Br J Urol 1997; 80: 27480.
  • 31
    Buckler H, Fraser W, Hosking D, Ryan W, Maricic MJ, Singer F, et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone 1999; 24: S815.
  • 32
    Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 74551.
  • 33
    Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997; 80: 22530.
  • 34
    Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999; 14: 155761.
  • 35
    Body JJ. Clinical research update: zoledronate. Cancer 1997; 80(Suppl): 1699701.
  • 36
    Fromigué O, Siwek B, Body JJ. Bisphosphonates inhibit breast cancer cell proliferation. Acta Clin Belg 1999; 114: 542.
  • 37
    Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 2209.
  • 38
    Boissier S, Magnetto S, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell invasion, but not tumor cell migration, through a mechanism independent of apoptosis induction [abstract SA128]. Bone 1998; 32: S558.
  • 39
    Marion G, Serre CM, Trzeciak MC, Delmas P, Clezardin P. Bisphosphonates inhibit the platelet-aggregating activity of tumor cells, a process involved during hematogenous dissemination of metastatic cells [abstract T330]. Bone 1998; 23: S279.
  • 40
    Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. Br J Cancer 1999; 80: 2218.
  • 41
    Coleman RE, Purohit OP, Black C, Vinholes JJSK, Huss H, Quinn KJ, et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 3116.
  • 42
    Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998; 34: 20216.
  • 43
    Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15: 1318.
  • 44
    Rosen LS, Lipton A, Savage A, Kowalski M, Miller JA, Knight R, et al. Phase I trial of zoledronate (CGP-42446), a new bisphosphonate, in patients with osteolytic bone lesions. Proc Am Soc Clin Oncol 1996; 15: 1570.
  • 45
    Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14: 792801.
  • 46
    Miura H, Yamamoto I, Takada M, Kigami Y, Ohta T, Yuu I, et al. Diagnostic validity of bone metabolic markers for bone metastasis. Endocr J 1997; 44: 7517.
  • 47
    Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 124350.
  • 48
    Foley KM. Supportive care and quality of life. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven Publishers, 1997: 280712.
  • 49
    Corso A, Serricchio G, Zappasodi P, Klersy C, Bosoni T, Moratti R, et al. Assessment of renal function in patients with multiple myeloma: the role of urinary proteins. Ann Hematol 1999; 78: 3715.
  • 50
    Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 178591.
  • 51
    Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 203844.
  • 52
    Hoggarth CR, Bennett R, Daley-Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int 1991; 49: 41620.
  • 53
    Cal JC, Daley-Yates PT. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology 1990; 65: 17997.
  • 54
    Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997; 30: 57393.
  • 55
    Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999; 45: 135968.
  • 56
    Lipton A, Berenson JR. Phase II open label, dose ranging, safety trial of rapid intravenous zoledronic acid, a novel bisphosphonate, in cancer patients with osteolytic bone metastases. In: Cancer-induced bone diseases, Second International Conference, Davoc, Switzerland. [Abstract] Volume 2. 1999:39.
  • 57
    Major P, Lortholary A, Hon J, Abdi E, Mills G, Meussen H, et al. Zoledronic acid is superior to pamidronate in the treatment of tumor-induced hypercalcemia: a pooled analysis. Proc Am Soc Clin Oncol 2000; 19: 605a.
  • 58
    Rogers MJ, Frith JC, Benford HL, Gordon S, Luckman SP, Helfrich M, et al. Molecular mechanisms of action of bisphosphonates [abstract]. Presented at: Second North American Symposium on Skeletal Complications of Malignancy, Montreal, Quebec, Canada, October 15–16, 1999.
  • 59
    Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 13140.
  • 60
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 147887.